Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy.

Thaxton CS, Elghanian R, Thomas AD, Stoeva SI, Lee JS, Smith ND, Schaeffer AJ, Klocker H, Horninger W, Bartsch G, Mirkin CA.

Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18437-42. doi: 10.1073/pnas.0904719106. Epub 2009 Oct 19.

2.

Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.

Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL, Rittenhouse HG.

Urology. 1997 Oct;50(4):573-9.

PMID:
9338734
3.

Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.

Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H.

J Urol. 1999 Apr;161(4):1206-11.

PMID:
10081870
4.

Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen.

Stamey TA, Graves HC, Wehner N, Ferrari M, Freiha FS.

J Urol. 1993 Apr;149(4):787-92.

PMID:
7681119
5.

The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy.

van Iersel MP, Thomas CM, Segers MF, Witjes WP, Debruyne FM, Oosterhof GO.

Br J Urol. 1996 Mar;77(3):418-22.

PMID:
8814849
6.
7.

Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.

Malik RD, Goldberg JD, Hochman T, Lepor H.

Eur Urol. 2011 Sep;60(3):548-53. doi: 10.1016/j.eururo.2011.05.036. Epub 2011 May 26.

PMID:
21652145
10.

Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.

Nakamura M, Hasumi H, Miyoshi Y, Sugiura S, Fujinami K, Yao M, Kubota Y, Uemura H.

Int J Urol. 2005 Dec;12(12):1050-4.

11.

Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up.

Vassilikos EJ, Yu H, Trachtenberg J, Nam RK, Narod SA, Bromberg IL, Diamandis EP.

Clin Biochem. 2000 Mar;33(2):115-23.

PMID:
10751589
12.
13.

Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy.

Egawa S, Matsumoto K, Suyama K, Soh S, Kuwao S, Iwamura M.

Urology. 1999 Jan;53(1):148-54.

PMID:
9886604
14.

Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.

Do T, Parker RG, Do C, Tran L, Do L, Dolkar D.

Cancer J Sci Am. 1998 Sep-Oct;4(5):324-30.

PMID:
9815297
15.

Ultrasensitive assay of prostate-specific antigen for early detection of residual cancer after radical prostatectomy.

Arai Y, Okubo K, Aoki Y, Maekawa S, Okada T, Maeda H.

Int J Urol. 1998 Nov;5(6):550-5.

18.

Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?

Godoy G, Tareen BU, Lepor H.

Urology. 2009 Jul;74(1):167-70. doi: 10.1016/j.urology.2008.07.067. Epub 2009 May 5.

PMID:
19406457
20.

Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay.

Haab F, Meulemans A, Boccon-Gibod L, Dauge MC, Delmas V, Hennequin C, Benbunan D, Boccon-Gibod L.

Urology. 1995 Jun;45(6):1022-7.

PMID:
7539559

Supplemental Content

Support Center